Award Number: W81XWH-04-1-0836 TITLE: Molecular Profiling of Prostate Cancer to Determine Predictive Markers of Response to Radiation and Receptor Tyrosine Kinase Inhibitor Therapy

@inproceedings{Kim2007AwardNW,
  title={Award Number: W81XWH-04-1-0836 TITLE: Molecular Profiling of Prostate Cancer to Determine Predictive Markers of Response to Radiation and Receptor Tyrosine Kinase Inhibitor Therapy},
  author={Dong Wook Kim},
  year={2007}
}
Purpose: To determine the efficacy of combining radiation (XRT) with a dual EGFR/VEGFR inhibitor, AEE788, in prostate cancer models with different levels of EGFR expression. Methods and Materials: Immunoblotting was performed for EGFR, phosphorylated-EGFR (p-EGFR), and p-AKT in prostate cancer cells. Clonogenic assays were performed on DU145, PC-3 and HUVEC cells treated with XRT+/-AEE788. Tumor xenografts were established for DU145 and PC-3 on hindlimbs of athymic nude mice assigned to four… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 41 REFERENCES

AEE788, a dual tyrosine kinase receptor inhibitor, induces endothelial cell apoptosis in human cutaneous squamous cell carcinoma xenografts in nude mice.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2005
VIEW 17 EXCERPTS
HIGHLY INFLUENTIAL

Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2005
VIEW 17 EXCERPTS
HIGHLY INFLUENTIAL

Targeted molecular therapy of anaplastic thyroid carcinoma with AEE788.

  • Molecular cancer therapeutics
  • 2005
VIEW 17 EXCERPTS
HIGHLY INFLUENTIAL

Similar Papers

Loading similar papers…